RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (2024)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/IB2023/050560, filed Jan 23, 2023. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,398,385 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| US 12,435,325 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| US 12,473,539 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| Application 19/268,552 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use Pending Not granted | Life Edit Therapeutics,Inc. | Pending | Not granted | ||
| Application 19/364,406 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use Pending Not granted | Life Edit Therapeutics, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Lifeedit, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.